Compare QUALCOMM, Inc. (QCOM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs TransMedics Group Inc — how do they compare? QUALCOMM, Inc. trades at $177.44 (market cap $182.87B), while TransMedics Group Inc trades at $70.87 (market cap $2.57B). The key difference: QUALCOMM, Inc. is far larger — about 71.2× TransMedics Group Inc's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| QCOM | TMDX | |
|---|---|---|
Market Cap | $182.87B | $2.57B |
Sector | Technology | Technology |
52-Week High | $251.10 | $150.42 |
52-Week Low | $124.07 | $61.99 |
Enterprise Value | $188.34B | $2.97B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $170.32, down 0.85% with bearish technical signals despite recent earnings beats. The stock shows strong fundamentals with 22.31% net margins and 29.27% ROE, though facing margin pressures and smartphone market headwinds. Recent news highlights AI diversification efforts through automotive and data center markets, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead.
Outlook remains mixed with 42.65% analyst buy ratings and $228.22 consensus target suggesting 34% upside, but technical weakness and competitive threats from Nvidia's PC chip entry create near-term uncertainty. Key risks include smartphone demand softness and margin compression, while AI expansion provides long-term growth potential.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
